论文部分内容阅读
目的探讨绝经前、后乳腺癌患者临床病理因素、血清3144 m/z蛋白峰表达水平的差异以及这些因素对乳腺癌患者生存的影响。方法用SELDI-TOF-MS技术检测术前乳腺癌患者血清3144 m/z蛋白峰的表达水平,对513例乳腺癌患者进行临床病理资料分析。结果绝经前、后乳腺癌患者血清3144 m/z蛋白峰阳性率分别为28.9%、32.7%,3144 m/z蛋白峰表达阳性的绝经后组乳腺癌患者预后最差,差异有统计学意义(P<0.05);绝经前组乳腺癌患者3144 m/z蛋白峰表达阳性和阴性的患者预后差异无统计学意义(P>0.05)。Cox多因素分析发现3144 m/z蛋白峰表达阳性是绝经后乳腺癌患者的独立预后因素,而绝经前乳腺癌患者预后主要与PR受体状态有关。绝经前后乳腺癌患者激素受体阳性率、妊娠次数以及流产史差异有统计学意义(P<0.05)。结论血清蛋白峰3144 m/z更适于监测绝经后乳腺癌患者的预后。
Objective To investigate the clinicopathological factors of breast cancer in premenopausal and post-menopausal women, the difference of the expression of serum 3144 m / z protein and the influence of these factors on the survival of patients with breast cancer. Methods SELDI-TOF-MS was used to detect the serum 3144 m / z protein peak in patients with preoperative breast cancer. The clinicopathological data of 513 breast cancer patients were analyzed. Results The positive rates of 3144 m / z protein in premenopausal and postmenopausal women with breast cancer were 28.9%, 32.7% and 3144 m / z, respectively. The postmenopausal breast cancer patients had the worst prognosis, the difference was statistically significant ( P <0.05). There was no significant difference in the prognosis of breast cancer patients with positive or negative 3144 m / z protein in premenopausal women (P> 0.05). Cox multivariate analysis showed that the positive expression of 3144 m / z protein peak was an independent prognostic factor in postmenopausal breast cancer patients, whereas the prognosis of premenopausal breast cancer patients was mainly related to PR receptor status. Pre and postmenopausal women with hormone receptor-positive rate, the number of pregnancies and miscarriage history was significantly different (P <0.05). Conclusion The serum protein peak 3144 m / z is more suitable for monitoring the prognosis of postmenopausal women with breast cancer.